Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation.

eLife - 19 Oct 2022

Park Hae J, Gregory Mark A, Zaberezhnyy Vadym, Goodspeed Andrew, Jordan Craig T, Kieft Jeffrey S, DeGregori James

Abstract excerpt

While leukemic cells are susceptible to various therapeutic insults, residence in the bone marrow microenvironment typically confers protection from a wide range of drugs. Thus, understanding the unique molecular changes elicited by the marrow is of critical importance toward improving therapeutic outcomes. In this study, we demonstrate that aberrant activation of oxidative phosphorylation serves to induce...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Everolimus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Oxidative Phosphorylation

Share to Protein Kinase Inhibitors

Share to TOR Serine-Threonine Kinases

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 36259537
DOI: 10.7554/eLife.79940
PMCID: PMC9645811

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation.PMID 36259537Read ↗

Quizartinib-induced resistance drives clonal emergence of MV4-11 cells with molecular alterations enabling multidrug antileukemic escape.Semantic proximity Read ↗

Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial.Semantic proximity Read ↗

P422: OMIPALISIB, A DUAL PI3K/MTOR INHIBITOR, TARGETS MITOCHONDRIA AND IMPAIRS OXIDATIVE PHOSPHORYLATION IN ACUTE MYELOID LEUKEMIASemantic proximity Read ↗

Adaptive resistance to FLT3 inhibitors is potentiated by ROS-driven DNA repair signallingSemantic proximity Read ↗

Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition.Semantic proximity Read ↗

Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AMLSemantic proximity Read ↗

Anti-leukemia effects of Omipalisib in Acute Myeloid Leukemia: inhibition of PI3K-AKT-mTOR signaling and suppression of Mitochondrial BiogenesisSemantic proximity Read ↗

Proteomics and Phosphoprotoemic Measurements Enhance Ability to Predict Ex Vivo Drug Response in AMLSemantic proximity Read ↗

Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AMLSemantic proximity Read ↗

Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AMLSemantic proximity Read ↗

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients.Semantic proximity Read ↗

Mutant U2AF1-Induced Mis-Splicing of mRNA Translation Genes Confers Resistance to Chemotherapy in Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.